Background: In several cancer models, it was shown that tumor mutation load correlates with response
to immune checkpoint blockade therapy. However, whole exome sequencing of FFPE samples
is not ideal for implementation on molecular pathology laboratories. In colorectal
cancer (CRC), mutation load is correlated with microsatellite instability (MSI), which
can therefore be used as surrogate marker for mutation load. In this study, we aimed
at determining whether a target NGS-based mutation panel can be used for routine testing
of mutation load in cancer, by assessing its performance in identifying MSI+ and MSI-
CRC samples.
To read this article in full you will need to make a payment
Purchase one-time access:
Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online accessOne-time access price info
- For academic or personal research use, select 'Academic and Personal'
- For corporate R&D use, select 'Corporate R&D Professionals'
Subscribe:
Subscribe to European Journal of CancerAlready a print subscriber? Claim online access
Already an online subscriber? Sign in
Register: Create an account
Institutional Access: Sign in to ScienceDirect
Article info
Publication history
Plenary Symposium 7: Monitoring of Immune response A9
Identification
Copyright
© 2018 Published by Elsevier Inc.
